From this morning’s radio interview with David Darling on the melanoma test commercialisation;
“The melanoma test could reach the market relatively soon”
“This particular opportunity lends itself nicely to a partnership with a company that might be developing a drug for melanoma, and in such a situation they look for new tools which we call campaign diagnostics and they use those companion diagnostics to sort patients going into the clinical studies to make sure they are getting those patients that will respond to the treatment.”
“So if they can use this test to segregate patients with recent tumours then put them into their clinical study they can determine how their new therapeutic will work and then subsequently if that therapeutic gets through to the market they’ll use the companion diagnostic on every patient that comes along with a melanoma to determine whether or not they will respond to the drug.”
Most new therapeutic developments by companies today require companion diagnostics so that’s a huge opportunity for the company, and so it may require only a limited amount of work by us in conjunction with a partner to bring about quite a significant commercial windfall”
Well, ....., and could that possible partner even be Roche ?
http://www.reuters.com/article/2014/...0FJ0HN20140714